To observe the clinical efficacy of Phentolamine-Mesilate combined Diammonium-Glycyrrhizinate in the treatment of chronic hepatitis gravis. 30 patients with chronic hepatitis gravis were randomly divided into treated group and control group. Treated group included 16 patients, treated by Phentolamine-Mesilate combined Diammonium-Glycyrrhizinate, and control group included 14 patients, treated by Diammonium-Glycyrrhizinate. The two groups were given other composite treatments. The whole treatment lasted 1 month, the clinical efficacy was observed and the results were analysed by statistics. The results showed that there weren't difference in serum total bilirubin (STB) and prothrombin active (PTA) between the two groups before treatment (P>0.05) . At the end of treatment, STB was lower and PTA was higher in treated group compared with control group (P<0.05) . STB of the two groups were lower (P<0.01, P<0.05) and PTA were higher (P<0.01) after treatment. Treated group was improved in therapeutic efficacy. Phentolamine-Mesilate combined Diammonium-Glycyrrhizinate has good clinical efficacy in the treatment of chronic hepatitis gravis.
DownLoad: